Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling

Angie Tong(Georgetown University), Marc D. Schwartz(Guardia Civil), Rachel Nusbaum(Icahn School of Medicine at Mount Sinai), Marie Wood(University of Colorado Cancer Center), Lina Jandorf(Icahn School of Medicine at Mount Sinai), Wendy McKinnon(University of Vermont), Shelley R. McCormick(Georgetown University), Scott P. Kelly(Pfizer (United States)), Kristi D. Graves(Georgetown University), Beth N. Peshkin(Georgetown University), Heiðdís Valdimarsdóttir(Reykjavík University), Judy E. Garber(Dana-Farber Cancer Institute)
Psycho-Oncology
May 17, 2014
10.1002/pon.3560
Cited by 29

Related Papers

Mutational Processes Molding the Genomes of 21 Breast Cancers
|Cell|2012|2k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k